Palvella Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Selling, General & Admin	22.29	15.76	5.94	3.08	4.16
Research & Development	35.46	22.84	8.15	8.79	13.88
Operating Expenses	57.74	38.6	14.1	11.87	18.04
Operating Income	-57.74	-38.6	-14.1	-11.87	-18.04
Interest Expense	-7.6	-5.82	-4.32	-	-10.36
Interest & Investment Income	4.19	2.59	0.64	6.27	-
Other Non Operating Income (Expenses)	-0.55	0.12	-0.76	1.2	-0.17
EBT Excluding Unusual Items	-61.7	-41.72	-18.53	-4.41	-28.58
Other Unusual Items	-	-	1.1	23.1	-
Pretax Income	-61.7	-41.72	-17.43	18.69	-28.58
Income Tax Expense	-	-	-	-	-1.03
Net Income	-61.7	-41.72	-17.43	18.69	-27.55
Preferred Dividends & Other Adjustments	-	-	-	14.81	-
Net Income to Common	-61.7	-41.72	-17.43	3.88	-27.55
Net Income Growth	-	-	-	-	-
Shares Outstanding (Basic)	13	11	2	2	6
Shares Outstanding (Diluted)	13	11	2	2	6
Shares Change	83.69%	405.46%	24.08%	-68.63%	-
EPS (Basic)	-4.90	-3.71	-7.83	2.19	-4.82
EPS (Diluted)	-4.90	-3.71	-7.83	2.17	-4.82
EPS Growth	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
EBIT	-57.74	-38.6	-14.1	-11.87	-18.04

SEC Filings: 10-K · 10-Q